Polatuzumab vedotin, an antibody-drug conjugate, selectively targets CD79b with a humanized anti-CD79b IgG1 monoclonal antibody bound to monomethyl auristatin E (MMAE), a robust microtubule inhibitor. This compound shows promise for research into Large B-cell lymphomas (LBCL) [1].
CAS Number:
[1313206-42-6]
Target:
Antibody-Drug Conjugates (ADCs)
T77823
* VAT and and shipping costs not included. Errors and price changes excepted
